Endothelial protein C receptor-associated invasiveness of rheumatoid synovial fibroblasts is likely driven by group V secretory phospholipase A2

详细信息    查看全文

• 作者：Meilang Xue (10)
  Kaitlin Shen (10)
  Kelly McKelvey (10)
  Juan Li (10)
  Yee-Ka Agnes Chan (10)
  Vicky Hatzis (10)
  Lyn March (11)
  Christopher B Little (12)
  Michael Tonkin (13)
  Christopher J Jackson (10)
  
• 刊名：Arthritis Research & Therapy
• 出版年：2014
• 出版时间：February 2014
• 年：2014
• 卷：16
• 期：1
• 全文大小：1,530 KB
• 参考文献：1. Noss EH, Brenner MB: The role and therapeutic implications of fibroblast-like synoviocytes in inflammation and cartilage erosion in rheumatoid arthritis. / Immunol Rev 2008, 223:252-70. CrossRef
  2. Huber LC, Distler O, Tarner I, Gay RE, Gay S, Pap T: Synovial fibroblasts: key players in rheumatoid arthritis. / Rheumatology 2006, 45:669-75. CrossRef
  3. Muller-Ladner U, Kriegsmann J, Franklin BN, Matsumoto S, Geiler T, Gay RE, Gay S: Synovial fibroblasts of patients with rheumatoid arthritis attach to and invade normal human cartilage when engrafted into SCID mice. / Am J Pathol 1996, 149:1607-615.
  4. Lefèvre S, Knedla A, Tennie C, Kampmann A, Wunrau C, Dinser R, Korb A, Schn?ker EM, Tarner IH, Robbins PD, Evans CH, Stürz H, Steinmeyer J, Gay S, Sch?lmerich J, Pap T, Müller-Ladner U, Neumann E: Synovial fibroblasts spread rheumatoid arthritis to unaffected joints. / Nat Med 2009, 15:1414-420. CrossRef
  5. Fukudome K, Esmon CT: Identification, cloning, and regulation of a novel endothelial cell protein c activated protein c receptor. / J Biol Chem 1994, 269:26486-6491.
  6. Bouwens EA, Mosnier LO: EPCR encryption induces cellular APC resistance. / Blood 2012, 119:2703-705. CrossRef
  7. Xue M, March L, Sambrook PN, Fukudome F, Jackson CJ: Endothelial protein C receptor is over-expressed in rheumatoid arthritic (RA) synovium and mediates the anti-inflammatory effects of activated protein C in RA monocytes. / Ann Rheum Dis 2007, 66:1574-580. CrossRef
  8. Esmon CT: Structure and functions of the endothelial cell protein C receptor. / Crit Care Med 2004, 32:S298-S301. CrossRef
  9. Gramling MW, Beaulieu LM, Church FC: Activated protein C enhances cell motility of endothelial cells and MDA-MB-231 breast cancer cells by intracellular signal transduction. / Exp Cell Res 2010, 316:314-28. CrossRef
  10. Ducros E, Mirshahi S, Azzazene D, Camilleri-Bro?t S, Mery E, Al Farsi H, Althawadi H, Besbess S, Chidiac J, Pujade-Lauraine E, Therwath A, Soria J, Mirshahi M: Endothelial protein C receptor expressed by ovarian cancer cells as a possible biomarker of cancer onset. / Int J Oncol 2012, 41:433-40.
  11. Antón I, Molina E, Luis-Ravelo D, Zandueta C, Valencia K, Ormazabal C, Martínez-Canarias S, Perurena N, Pajares MJ, Agorreta J, Montuenga LM, Segura V, Wistuba II, De Las Rivas J, Hermida J, Lecanda F: Receptor of activated protein C promotes metastasis and correlates with clinical outcome in lung adenocarcinoma. / Am J Respir Crit Care Med 2012, 186:96-05. CrossRef
  12. Xu J, Qu D, Esmon NL, Esmon CT: Metalloproteolytic release of endothelial cell protein C receptor. / J Biol Chem 2000, 275:6038-044. CrossRef
  13. Qu D, Wang Y, Esmon NL, Esmon CT: Regulated endothelial protein C receptor shedding is mediated by tumor necrosis factor-alpha converting enzyme/ADAM17. / J Thromb Haemost 2007, 5:395-02. CrossRef
  14. Liaw PC, Neuenschwander PF, Smirnov MD, Esmon CT: Mechanisms by which soluble endothelial cell protein C receptor modulates protein C and activated protein C function. / J Biol Chem 2000, 275:5447-452. CrossRef
  15. Kurosawa S, Stearnskurosawa DJ, Carson CW, Dangelo A, Dellavalle P, Esmon CT: Plasma levels of endothelial cell protein c receptor are elevated in patients with sepsis and systemic lupus erythematosus - lack of correlation with thrombomodulin suggests involvement of different pathological processes. / Blood 1998, 91:725-27.
  16. Gu JM, Katsuura Y, Ferrell GL, Grammas P, Esmon CT: Endotoxin and thrombin elevate rodent endothelial cell protein C receptor mRNA levels and increase receptor shedding in vivo. / Blood 2000, 95:1687-693.
  17. Bilgic A, Ozdemir FN, Bayraktar N, Karakus S, Sasak G, Arat Z, Sezer S, Haberal M: Soluble endothelial protein C receptor: influence on arteriovenous fistula thrombosis development in hemodialysis patients. / Am J Nephrol 2007, 27:366-72.
  18. Lopez-Sagaseta J, Puy C, Tamayo I, Allende M, Cervero J, Velasco SE, Esmon CT, Montes R, Hermida J: sPLA2-V inhibits EPCR anticoagulant and antiapoptotic properties by accommodating lysophosphatidylcholine or PAF in the hydrophobic groove. / Blood 2012, 119:2914-921. CrossRef
  19. Pruzanski W, Vadas P: Phospholipase A2-a mediator between proximal and distal effectors of inflammation. / Immunol Today 1991, 12:143-46.
  20. Leistad L, Feuerherm AJ, Ostensen M, Faxvaag A, Johansen B: Presence of secretory group IIa and V phospholipase A2 and cytosolic group IValpha phospholipase A2 in chondrocytes from patients with rheumatoid arthritis. / Clin Chem Lab Med 2004, 42:602-10. CrossRef
  21. Masuda S, Murakami M, Komiyama K, Ishihara M, Ishikawa Y, Ishii T, Kudo I: Various secretory phospholipase A2 enzymes are expressed in rheumatoid arthritis and augment prostaglandin production in cultured synovial cells. / FEBS J 2005, 272:655-72. CrossRef
  22. Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, Christy W, Cooke TD, Greenwald R, Hochberg M: Development of criteria for the classification and reporting of osteoarthritis, Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. / Arthritis Rheum 1986, 8:49.
  23. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. / Arthritis Rheum 1988, 31:315-24. CrossRef
  24. Herron GS, Banda MJ, Clark EJ, Gavrilovic J, Werb Z: Secretion of metalloproteinases by stimulated capillary endothelial cells. II. Expression of collagenase and stromelysin activities is regulated by endogenous inhibitors. / J Biol Chem 1986, 261:2814-818.
  25. Korff T, Augustin HG: Tensional forces in fibrillar extracellular matrices control directional capillary sprouting. / J Cell Sci 1999, 112:3249-258.
  26. Xue M, Chan YK, Shen K, Dervish S, March L, Sambrook PN, Jackson CJ: Protease-activated receptor 2, rather than protease-activated receptor 1, contributes to the aggressive properties of synovial fibroblasts in rheumatoid arthritis. / Arthritis Rheum 2012, 64:88-8. CrossRef
  27. Schmitz N, Laverty S, Kraus VB, Aigner T: Basic methods in histopathology of joint tissues. / Osteoarthritis Cartilage 2010, 18:S113-S116. CrossRef
  28. Farndale RW, Buttle DJ, Barrett AJ: Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylmethylene blue. / Biochim Biophys Acta 1986, 883:173-77. CrossRef
  29. Korb-Pap A, Stratis A, Mühlenberg K, Niederreiter B, Hayer S, Echtermeyer F, Stange R, Zwerina J, Pap T, Pavenst?dt H, Schett G, Smolen JS, Redlich K: Early structural changes in cartilage and bone are required for the attachment and invasion of inflamed synovial tissue during destructive inflammatory arthritis. / Ann Rheum Dis 2012, 71:1004-011. CrossRef
  30. Nguyen M, Arkell J, Jackson CJ: Activated protein C directly activates human endothelial gelatinase A. / J Biol Chem 2000, 275:9095-098. CrossRef
  31. Goldring SR: Pathogenesis of bone and cartilage destruction in rheumatoid arthritis. / Rheumatology (Oxford) 2003, 42:11-6. CrossRef
  32. Pretzel D, Pohlers D, Weinert S, Kinne RW: In vitro model for the analysis of synovial fibroblast-mediated degradation of intact cartilage. / Arthritis Res Ther 2009, 11:R25. CrossRef
  33. Lee DM, Kiener HP, Agarwal SK, Noss EH, Watts GF, Chisaka O, Takeichi M, Brenner MB: Cadherin-11 in synovial lining formation and pathology in arthritis. / Science 2007, 315:1006-010. CrossRef
  34. Schett G, Tohidast-Akrad M, Smolen JS, Schmid BJ, Steiner CW, Bitzan P, Zenz P, Redlich K, Xu Q, Steiner G: Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-JUN N-terminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthritis. / Arthritis Rheum 2000, 43:2501-512. CrossRef
  35. Zhang Y, Dong J, He P, Li W, Zhang Q, Li N, Sun T: Genistein inhibit cytokines or growth factor-induced proliferation and transformation phenotype in fibroblast-like synoviocytes of rheumatoid arthritis. / Inflammation 2012, 35:377-87. CrossRef
  36. Han Z, Boyle DL, Chang L, Bennett B, Karin M, Yang L, Manning AM, Firestein GS: c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. / J Clin Invest 2001, 108:73-1. CrossRef
  37. de Launay D, van de Sande MG, de Hair MJ, Grabiec AM, van de Sande GP, Lehmann KA, Wijbrandts CA, van Baarsen LG, Gerlag DM, Tak PP, Reedquist KA: Selective involvement of ERK and JNK mitogen-activated protein kinases in early rheumatoid arthritis (1987 ACR criteria compared to 2010 ACR/EULAR criteria): a prospective study aimed at identification of diagnostic and prognostic biomarkers as well as therapeutic targets. / Ann Rheum Dis 1987, 2012:415-23.
  38. Gortz B, Hayer S, Tuerck B, Zwerina J, Smolen JS, Schett G: Tumour necrosis factor activates the mitogen-activated protein kinases p38alpha and ERK in the synovial membrane in vivo. / Arthritis Res Ther 2005, 7:R1140-R1147. CrossRef
  39. Gleeson EM, O'Donnell JS, Preston RJ: The endothelial cell protein C receptor: cell surface conductor of cytoprotective coagulation factor signaling. / Cell Mol Life Sci 2012, 69:717-26. CrossRef
  40. Joosten LA, Helsen MM, Saxne T, van De Loo FA, Heinegard D, van Den Berg WB: IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation. / J Immunol 1999, 163:5049-055.
  41. Trebec-Reynolds DP, Voronov I, Heersche JN, Manolson MF: IL-1alpha and IL-1beta have different effects on formation and activity of large osteoclasts. / J Cell Biochem 2010, 109:975-82.
  42. Criswell LA: Gene discovery in rheumatoid arthritis highlights the CD40/NF-kappaB signaling pathway in disease pathogenesis. / Immunol Rev 2010, 233:55-1. CrossRef
  43. Xue M, Minhas N, Chow SO, Dervish S, Sambrook PN, March L, Jackson CJ: Endogenous protein C is essential for the functional integrity of human endothelial cells. / Cell Mol Life Sci 2010, 67:1537-546. CrossRef
  44. Itoh T, Matsuda H, Tanioka M, Kuwabara K, Itohara S, Suzuki R: The role of matrix metalloproteinase-2 and matrix metalloproteinase-9 in antibody-induced arthritis. / J Immunol 2002, 169:2643-647.
  45. Bezuhly M, Cullen R, Esmon CT, Morris SF, West KA, Johnston B, Liwski RS: Role of activated protein C and its receptor in inhibition of tumor metastasis. / Blood 2009, 113:3371-374. CrossRef
  46. Menschikowski M, Hagelgans A, Eisenhofer G, Siegert G: Regulation of endothelial protein C receptor shedding by cytokines is mediated through differential activation of MAP kinase signaling pathways. / Exp Cell Res 2009, 315:2673-682. CrossRef
  47. Wu J, Zhou Z, Ye S, Dai H, Ma L, Xu X, Li X: Detection of soluble endothelial protein C receptor (sEPCR) in patients with CHD, DM and SLE. / Zhonghua XueYeXueZa Zhi 2000, 21:472-74.
  48. Ducros E, Mirshahi SS, Faussat AM, Mirshahi P, Dimicoli S, Tang R, Pardo J, Ibrahim J, Marie JP, Therwath A, Soria J, Mirshahi M: Soluble endothelial protein C receptor (sEPCR) is likely a biomarker of cancer-associated hypercoagulability in human hematologic malignancies. / Cancer Med 2012, 1:261-67. CrossRef
  49. Montes R, Puy C, Molina E, Hermida J: Is EPCR a multi-ligand receptor? Pros and cons. / Thromb Haemost 2012, 107:815-26. CrossRef
  
• 作者单位：Meilang Xue (10)
  Kaitlin Shen (10)
  Kelly McKelvey (10)
  Juan Li (10)
  Yee-Ka Agnes Chan (10)
  Vicky Hatzis (10)
  Lyn March (11)
  Christopher B Little (12)
  Michael Tonkin (13)
  Christopher J Jackson (10)
  
  10. Sutton Arthritis Research Laboratories, The University of Sydney at Royal North Shore Hospital, Pacific Highway, St Leonards, NSW, 2065, Australia
  11. Department of Rheumatology, The University of Sydney at Royal North Shore Hospital, Pacific Highway, St Leonards, NSW, 2065, Australia
  12. Raymond Purves Research Laboratory, The University of Sydney at Royal North Shore Hospital, Pacific Highway, St Leonards, NSW, 2065, Australia
  13. Department of Surgery, Kolling Institute of Medical Research, The University of Sydney at Royal North Shore Hospital, Pacific Highway, St Leonards, NSW, 2065, Australia
  
• ISSN：1478-6354

文摘

Introduction Rheumatoid synovial fibroblasts (RASFs) mediate joint inflammation and destruction in rheumatoid arthritis (RA). Endothelial protein C receptor (EPCR) is a specific receptor for the natural anticoagulant activated protein C (APC). It mediates the cytoprotective properties of APC and is expressed in rheumatoid synovial tissue. A recent report shows that group V secretory phospholipase A2 (sPLA2V) prevents APC from binding to EPCR in endothelium and inhibits EPCR/APC function. The aim of this study was to investigate the expression and function of EPCR on RASFs. Methods Human synovial fibroblasts (SFs) were isolated from RA or osteoarthritis (OA) synovial tissues and treated with control, EPCR, or sPLA2V small interfering RNA (siRNA); recombinant human APC, tumor necrosis factor-alpha (TNF-α), or sPLA2V. RASF viability and migration/invasion were measured by 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) and collagen gel migration/invasion assays, respectively, and cartilage degradation by 1,9-dimethylmethylene blue (DMMB) assay in the presence of human OA articular cartilage explants. The expression or activation of cytokines, EPCR, cadherin-11, mitogen-activated protein (MAP) kinases, and nuclear factor-kappa-B (NF-κB) or both were detected by enzyme-linked immunosorbent assay, Western blotting, or immunostaining. Results EPCR was expressed by both OASFs and RASFs but was markedly increased in RASFs. When EPCR was suppressed by siRNA or blocking antibody cell viability, cell invasion and cartilage degradation were reduced by more than 30%. Inflammatory mediators interleukin-1-beta (IL-1β), cadherin-11, and NF-κB were significantly reduced by EPCR suppression under control or TNF-α-stimulated conditions. The expression or activation (or both) of MAP kinases ERK, p38, and JNK were also markedly decreased in cells transfected with EPCR siRNA. Further analysis revealed that sPLA2V co-localized with EPCR on RASFs. Suppression of sPLA2V reduced cell viability and cartilage degradation and increased APC binding to RASFs. Conversely, recombinant sPLA2V increased cartilage degradation, blocked APC binding to RASFs, and could not rescue the effects induced by EPCR suppression. Conclusions Our results demonstrate that EPCR is overexpressed by RASFs and mediates the aggressive behavior of RASFs. This function of EPCR is contrary to its cytoprotective role in other settings and is likely driven by sPLA2V.